<DOC>
	<DOCNO>NCT01379989</DOCNO>
	<brief_summary>The objective multicentric , randomise , Phase III study demonstrate superiority , term prolong survival , trabectedin Pegylated Liposomal Doxorubicin ( PLD ) versus carboplatin PLD . Patients randomise : Arm A : PLD 30 mg/m2 carboplatin AUC 5 Arm B : PLD 30 mg/m2 trabectedin 1.1 mg/m2 Patients'/subjects ' characteristic : patient 18 year age advance , progressive ovarian cancer 6-12 month completion first line treatment platinum-based chemotherapy .</brief_summary>
	<brief_title>INOVATYON STUDY -International , Randomized Study Patients With Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>1 . Female , age ≥ 18 year 2 . Histologically and/or cytologically proven epithelial ovarian , epithelial fallopian tube cancer primary peritoneal cancer 3 . Progression free interval six twelve ( 612 ) month ( calculate first day last cycle last platinumbased chemotherapy date progression confirmation radiologic imagery ) . Patients may receive two platinumbased chemotherapy line , least one must contain taxane 4 . Measurable evaluable disease confirm radiological imaging , magnetic resonance imaging ( MRI ) , compute tomography ( CT ) scan , PET/CT scan study entry ( CA125 rise support radiological evidence disease accept criterion define progression ) histological proven recurrent ovarian cancer even absence postoperatively measurable evaluable lesion . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) ≤ 2 6 . Estimated life expectancy ≥ 12 week 7 . Patients must accessible treatment followup 8 . Adequate organ function within 14 day prior first cycle evidence 9 . Patients must able receive dexamethasone equivalent , require randomly assign treatment trabectedin plus PLD 10 . Informed consent patient 1 . Non epithelial ovarian mixed epithelial/non epithelial tumor ( e.g. , Mullerian tumor ) 2 . Patients respond last platinumbased therapy last relapse occur &lt; 6 month &gt; 12 month last dose platinum 3 . Bowel obstruction , subocclusive disease presence symptomatic brain metastasis 4 . Preexisting grade &gt; 1 motor sensory neuropathy accord National Cancer Institute Common Toxicity Criteria Adverse Event ( NCICTCAE ) version 4.0 5 . Myocardial infarct within six month enrolment , New York Association ( NYHA ) Class II bad heart failure ( Appendix 1 . The New York Heart Association ) , uncontrolled angina , severe uncontrolled ventricular arrythmias , clinically significant pericardial disease , electrocardiographic evidence acute ischemic active conduction system abnormalities 6 . History liver disease 7 . Concurrent severe medical problem unstable medical condition unrelated malignancy , would significantly limit full compliance study expose patient extreme risk decrease life expectancy 8 . Breastfeeding woman woman child bear potential must use effective contraception treatment 3 month thereafter , may include prescription contraceptive ( oral , injection , patch ) , intrauterine device , doublebarrier method male partner sterilization ( applicable patient surgically sterile ) 9 . Prior exposure trabectedin 10 . Prior resistance anthracyclines PLD define progression anthracyclinebased chemotherapy recurrence within 6 month end 11 . Prior severe PLD related toxicity 12 . Prior exposure cumulative dos doxorubicin &gt; 400mg/m2 epirubicin &gt; 720mg/m2 13 . Treatment investigational product within 30 day prior inclusion study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>